{'fraction_non_alphanumeric': 0.03076923076923077, 'fraction_numerical': 0.00805860805860806, 'mean_word_length': 4.812765957446809, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In-silico identification and analysis of hub proteins for designing novel first line anti-seizure medications



Epilepsy is a seizure related disease with different symptoms and types, depending on the origin and propagation region of brain. There are several marketed anti-seizure medications (ASMs) available for choice of treatment by clinicians but there is a huge paucity of ideal 1st line ASMs.



The present study was undertaken to identify and get an in-sight into the major target (hub) proteins, which can be comprehensively used as platform for designing first line ASMs.



Large-scale text-mining was done to generate a data warehouse of available ASMs and their MOAs, followed by identification of specific isoforms of target proteins for designing next generation ASMs, using network biology and other in-silico approaches.



The study resulted in identification of 3 major classes of target proteins of major ASMs and their specific isoforms, namely – GABA receptors (GABRA1, GABRB1 and GABARAP); VGSC (α-subunit SCN2A (Nav1.2)) and VGCC (α-subunitCACNA1G (Cav3.1)). The identified proteins were also observed to be concurrent with the target sites of majorly sold ASMs currently.



The predicted hub protein families and their specific isoforms can be further validated and comprehensively used to design next generation novel 1st line ASM(s).
